- Home
- SSP vs ABOS Comparison
SSP vs ABOS Comparison
Compare SSP & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SSP | ABOS |
|---|---|---|
| Founded | 1878 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 395.2M | 113.9M |
| IPO Year | 1988 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SSP | ABOS |
|---|---|---|
| Price | $3.96 | $2.11 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $5.50 | ★ $7.67 |
| AVG Volume (30 Days) | ★ 986.5K | 154.4K |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,318,706,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.11 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.36 | $0.86 |
| 52 Week High | $4.98 | $2.46 |
Technical Indicators
Market Signals| Indicator | SSP | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 45.61 | 55.67 |
| Support Level | $3.88 | $2.01 |
| Resistance Level | $4.98 | $2.39 |
| Average True Range (ATR) | 0.35 | 0.13 |
| MACD | -0.14 | 0.02 |
| Stochastic Oscillator | 7.24 | 50.93 |
Price Performance
Historical ComparisonAbout SSP E.W. Scripps Company (The)
The E W Scripps Co is a media enterprise with interests in local and national media brands. It owns and operates a collection of daily and community newspapers in medium-sized cities in the southern and western portions of the United States. The company's operating segment includes Local Media, Scripps Networks, and Other. It generates maximum revenue from the Local Media segment. The Local Media segment includes local broadcast stations and their related digital operations.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.